Loading…
Apogee Therapeutics, Inc. is projected to rise to $194.23 by 2027, a +45% move from its current price of $134.30. APGE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $132.06 | $134.32 | $136.63 | +0.02% |
| Aug 2 | $131.15 | $134.35 | $137.62 | +0.04% |
| Aug 3 | $130.47 | $134.37 | $138.39 | +0.05% |
| Aug 4 | $129.90 | $134.39 | $139.04 | +0.07% |
| Aug 5 | $129.40 | $134.42 | $139.63 | +0.09% |
| Aug 6 | $128.96 | $134.44 | $140.16 | +0.11% |
| Aug 7 | $128.55 | $134.46 | $140.65 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $128.55 | $134.46 | $140.65 | +0.12% |
| Week 2 | $126.33 | $134.63 | $143.48 | +0.25% |
| Week 3 | $124.69 | $134.79 | $145.72 | +0.37% |
| Week 4 | $123.34 | $134.96 | $147.67 | +0.49% |
| Week 5 | $122.19 | $135.13 | $149.43 | +0.61% |
| Week 6 | $121.17 | $135.29 | $151.06 | +0.74% |
| Week 7 | $120.25 | $135.46 | $152.58 | +0.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apogee Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications in the United States. It develops Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
APGE is a healthcare company trading at $134.26 with a market cap of $10.09B and a rank of 891. The current price places APGE among healthcare equities with a relatively large market capitalization. The forecast implies substantial upside over the coming years, with 2026 shown as a baseline year and stronger bullish momentum evident from 2027 onward.
The 2026 average price is $134.26, with a 30-day range of $117.78 to $153.05.
A major floor 45.6% below — a decisive break under it would weaken the trend.
The nearest floor, 34.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 22.8% above — clearing it would confirm fresh momentum.
Key APGE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APGE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $134.25 | Buy | $134.23 | Buy |
| MA 10 | $134.19 | Buy | $133.98 | Buy |
| MA 20 | $133.92 | Buy | $131.02 | Buy |
| MA 50 | $111.65 | Buy | $117.27 | Buy |
| MA 100 | $96.60 | Buy | $102.56 | Buy |
| MA 200 | $82.53 | Buy | $86.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 80.06 | Sell |
| Stoch RSI (14) | 12.18 | Buy |
| CCI (20) | 77.47 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -1.66 | Sell |
| ROC (12) | 0.25 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.91 | Buy |
| Awesome (5,34) | 8.72 | Buy |
| Ultimate (7,14,28) | 67.39 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 134.25 | Buy |
| ADX (14) | 55.06 | Buy |
| ATR (14) | 0.84 | Info |
The 30-day technical picture is bullish overall. RSI14 is 80, indicating strong near-term momentum. APGE trades above the SMA50 of $106.44 and above the SMA200 of $80.34, signaling upside pressure. Near-term support is at $82.72 and resistance at $134.29. The 30-day range trades between $117.78 and $153.05.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.13 | $134.30 | $181.11 | 0% | Neutral | |
| $159.25 | $194.23 | $247.53 | +45% | Bullish | |
| $202.31 | $251.44 | $329.25 | +87% | Bullish | |
| $233.54 | $294.77 | $394.30 | +119% | Bullish | |
| $271.40 | $347.21 | $472.87 | +159% | Bullish | |
| $295.76 | $383.02 | $529.94 | +185% | Bullish | |
| $322.97 | $423.00 | $593.62 | +215% | Bullish | |
| $378.42 | $500.86 | $712.03 | +273% | Bullish | |
| $460.08 | $615.02 | $884.81 | +358% | Bullish | |
| $536.10 | $723.44 | $1,052.42 | +439% | Bullish | |
| $785.90 | $1,106.21 | $1,686.63 | +724% | Bullish | |
| $1,690.82 | $2,552.67 | $4,172.52 | +18.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.13 | $134.30 | $156.49 | +0.00% |
| August 2026 | $117.39 | $136.88 | $162.65 | +1.92% |
| September 2026 | $116.36 | $136.46 | $163.68 | -0.30% |
| October 2026 | $119.13 | $140.35 | $169.60 | +2.85% |
| November 2026 | $124.03 | $146.67 | $178.31 | +4.51% |
| December 2026 | $124.87 | $148.17 | $181.11 | +1.02% |
Click any year to see its month-by-month APGE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APGE price prediction for 2026 points to an average of $134.30 (low $62.13, high $181.11) — a potential gain of 0% on today's $134.30. Price action looks broadly range-bound.
In 2027, APGE is projected to trade between $159.25 and $247.53, averaging $194.23 — a potential gain of +45% from today's $134.30. That is up +45% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Apogee Therapeutics, Inc.'s 2028 outlook centres on $251.44, within a $202.31 to $329.25 range. That is up +29% on the projected 2027 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2029, APGE could reach as high as $394.30, with a base case around $294.77 and support toward $233.54 — roughly +119% from $134.30. Buyers look set to stay in control over this stretch.
Expect APGE to range from $271.40 to $472.87 through 2030. The $347.21 average target implies a +159% move from current prices. That is up +18% on the projected 2029 average. Momentum favours further upside here.
The APGE price prediction for 2031 points to an average of $383.02 (low $295.76, high $529.94) — a potential gain of +185% on today's $134.30. Buyers look set to stay in control over this stretch.
In 2032, APGE is projected to trade between $322.97 and $593.62, averaging $423.00 — a potential gain of +215% from today's $134.30. That is up +10% on the projected 2031 average. Momentum favours further upside here.
Apogee Therapeutics, Inc.'s 2033 outlook centres on $500.86, within a $378.42 to $712.03 range. That is up +18% on the projected 2032 average. That marks a +273% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, APGE could reach as high as $884.81, with a base case around $615.02 and support toward $460.08 — roughly +358% from $134.30. Momentum favours further upside here.
Expect APGE to range from $536.10 to $1,052.42 through 2035. The $723.44 average target implies a +439% move from current prices. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The APGE price prediction for 2040 points to an average of $1,106.21 (low $785.90, high $1,686.63) — a potential gain of +724% on today's $134.30. Momentum favours further upside here.
In 2050, APGE is projected to trade between $1,690.82 and $4,172.52, averaging $2,552.67 — a potential gain of +18.0x from today's $134.30. That is up +131% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in APGE today (≈ 7.446016 APGE) could be worth
$19,007.2
+$18,007.2 (+1801%) by 2050 · US Dollar
Based on the average projected APGE price of $2,552.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APGEwould be worth at today's price.
$1,000 invested in APGE on Jul 30, 2025 (≈ 26.588673 APGE) would be worth
$3,570.86
+$2,570.86 (+257.1%) today · 3.57× · US Dollar
Based on a APGE entry price of $37.61 vs. today's $134.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $134.26 | $1,000.3 | +0.0% |
| 1 month ago | $132.73 | $1,011.83 | +1.2% |
| 3 months ago | $80.75 | $1,663.16 | +66.3% |
| 6 months ago | $65.51 | $2,050.07 | +105.0% |
| 1 year ago | $37.61 | $3,570.86 | +257.1% |
| All time (3.0y) ago | $21.23 | $6,325.95 | +532.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APGE forecast.
Our base-case forecast reaches $270.00 around 2029.
Implied market cap at $270.00: $16.66B
The multi-year forecast shows a bullish trajectory with rising average prices across years. In 2027 the average price is $193.35 with a 44% return outlook and bullish sentiment; in 2028 the average is $250.86 with 86.8% ROI and bullish sentiment; in 2029 the average is $291.38 with 117% ROI; in 2030 the average is $344.73 with 156.8% ROI. The upward path continues with 2031 at $378.96 (182.3% ROI) and 2032 at $413.86 (208.3% ROI).
By 2033 the average is $494.51 (268.3% ROI) and 2034 $602.76 (348.9% ROI), culminating in 2040 with $1,074.42 average (700.3% ROI) and 2050 at $2,460.37 average (1732.5% ROI). The sentiment remains bullish across these years, though these figures are estimates and not guarantees; actual results depend on numerous factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $344.73, with a min of $267.73 and a max of $473.45, and a 156.8% ROI; sentiment is bullish.
Forecasts show bullish sentiment from 2027 onward, with a 2030 average of $344.73 and ROI of 156.8%; long-term views project substantial upside to 2040 and 2050 (e.g., $1,074.42 average in 2040 and $2,460.37 average in 2050). These are estimates, not guarantees.
Yes. The max forecast for 2030 is $473.45.
RSI14 is 80; SMA50 is $106.44; SMA200 is $80.34; support is $82.72 and resistance is $134.29. The 30-day range is $117.78 to $153.05; sentiment is bullish.
Current price is $134.26 and market cap is $10.09B.
Apogee Therapeutics, Inc. Community Discussion
0Share your Apogee Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.